Eloxx Pharmaceuticals Posts $5.54M Q3 Net Loss, Reports $56.3M Cash
Eloxx Pharmaceuticals reported a third-quarter 2026 net loss of $5.54 million, or $0.49 per share, and cash and cash equivalents of $56.3 million at September 30. The company dosed the first two patients in its Phase 2b Alport syndrome study and received FDA clearance for its planned ADPKD study. I…